Cell and Gene Therapy in Parkinson’s Disease- Pipeline Insight,2025
Description
DelveInsight’s, “Cell and Gene Therapy in Parkinson’s Disease - Pipeline Insight, 2025” report provides comprehensive insights about 18+ companies and 20+ pipeline drugs in Cell and Gene Therapy in Parkinson’s Disease pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Cell and Gene Therapy in Parkinson’s Disease: Overview
According to the Parkinson’s Foundation, Parkinson’s disease is a neurodegenerative disorder that affects predominately dopamine-producing (dopaminergic) neurons in a specific area of the brain called the substantia nigra. Because Parkinson’s disease develops over time, various stages help identify how symptoms have progressed and what should be expected next. Generally, there are five stages of Parkinson’s disease: Stage I, Stage II, Stage III, Stage IV, and Stage V.
According to the National Health Service (NHS), there are many different symptoms associated with Parkinson’s disease. The main symptoms referred to by doctors as parkinsonism include tremors, slowness of movement (bradykinesia), and muscle stiffness (rigidity), which are classified as motor symptoms while non-motor symptoms include cognitive changes, autonomic dysfunctioning, mood and sleep disorders, and others.
Several mechanisms have been implicated in Parkinson’s disease pathogenesis, with α-synuclein aggregation central to the development of the disease. Multiple other processes are thought to be involved, with several studies suggesting that abnormal protein clearance, mitochondrial dysfunction, and neuroinflammation play a role in the onset and progression of Parkinson’s disease. However, the relationship between these pathways remains unclear. Native α-synuclein in the brain is mostly unfolded without a defined tertiary structure, although in aqueous solutions, it can be present in stable tetramers that resist aggregation.
At present, there is no definitive test for Parkinson’s disease. However, there are various symptoms and diagnostic tests used in combination. Making an accurate diagnosis of Parkinson’s – particularly in its early stages – is difficult, but a skilled practitioner can conclude it is Parkinson’s disease. There is no one way to diagnose Parkinson’s disease; however, it can often be identified by a general neurologist trained to diagnose and treat neurologic disorders. To avoid misdiagnosis, consultation with a movement disorder specialist (MDS) is recommended. Medications are the most common therapy for Parkinson’s disease. The goal is to correct the shortage of dopamine; this deficiency causes the symptoms. Pharmacological treatment is usually started when symptoms become disabling or disrupt daily activities. Treatments may differ according to the patient’s symptoms, age, and responses to specific drugs. Finding the best combination of drugs for each patient takes time. Levodopa (L-dopa, l-3, 4-dihydroxyphenylalanine), the metabolic precursor of dopamine, is the single most effective agent for treating Parkinson’s disease. Levodopa is largely inert; its therapeutic and adverse effects result from the decarboxylation of levodopa to dopamine. Furthermore, a new area being explored in the treatment of Parkinson’s disease is gene therapy. Both non-disease and disease-modifying transgenes are being researched.
""Cell and Gene Therapy in Parkinson’s Disease- Pipeline Insight, 2025"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Cell and Gene Therapy in Parkinson’s Disease pipeline landscape is provided which includes the disease overview and Cell and Gene Therapy in Parkinson’s Disease treatment guidelines. The assessment part of the report embraces, in depth Cell and Gene Therapy in Parkinson’s Disease commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Cell and Gene Therapy in Parkinson’s Disease collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Cell and Gene Therapy in Parkinson’s Disease report encloses its detailed analysis of various drugs in different stages of clinical development, including Phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Cell and Gene Therapy in Parkinson’s Disease Emerging Drugs
Further product details are provided in the report……..
Cell and Gene Therapy in Parkinson’s Disease: Therapeutic Assessment
This segment of the report provides insights about the different Cell and Gene Therapy in Parkinson’s Disease drugs segregated based on following parameters that define the scope of the report, such as:
Cell and Gene Therapy in Parkinson’s Disease: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Cell and Gene Therapy in Parkinson’s Disease therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Cell and Gene Therapy in Parkinson’s Disease drugs.
Cell and Gene Therapy in Parkinson’s Disease Report Insights
Current Treatment Scenario and Emerging Therapies:
Geography Covered
- Global coverage
Cell and Gene Therapy in Parkinson’s Disease: Overview
According to the Parkinson’s Foundation, Parkinson’s disease is a neurodegenerative disorder that affects predominately dopamine-producing (dopaminergic) neurons in a specific area of the brain called the substantia nigra. Because Parkinson’s disease develops over time, various stages help identify how symptoms have progressed and what should be expected next. Generally, there are five stages of Parkinson’s disease: Stage I, Stage II, Stage III, Stage IV, and Stage V.
According to the National Health Service (NHS), there are many different symptoms associated with Parkinson’s disease. The main symptoms referred to by doctors as parkinsonism include tremors, slowness of movement (bradykinesia), and muscle stiffness (rigidity), which are classified as motor symptoms while non-motor symptoms include cognitive changes, autonomic dysfunctioning, mood and sleep disorders, and others.
Several mechanisms have been implicated in Parkinson’s disease pathogenesis, with α-synuclein aggregation central to the development of the disease. Multiple other processes are thought to be involved, with several studies suggesting that abnormal protein clearance, mitochondrial dysfunction, and neuroinflammation play a role in the onset and progression of Parkinson’s disease. However, the relationship between these pathways remains unclear. Native α-synuclein in the brain is mostly unfolded without a defined tertiary structure, although in aqueous solutions, it can be present in stable tetramers that resist aggregation.
At present, there is no definitive test for Parkinson’s disease. However, there are various symptoms and diagnostic tests used in combination. Making an accurate diagnosis of Parkinson’s – particularly in its early stages – is difficult, but a skilled practitioner can conclude it is Parkinson’s disease. There is no one way to diagnose Parkinson’s disease; however, it can often be identified by a general neurologist trained to diagnose and treat neurologic disorders. To avoid misdiagnosis, consultation with a movement disorder specialist (MDS) is recommended. Medications are the most common therapy for Parkinson’s disease. The goal is to correct the shortage of dopamine; this deficiency causes the symptoms. Pharmacological treatment is usually started when symptoms become disabling or disrupt daily activities. Treatments may differ according to the patient’s symptoms, age, and responses to specific drugs. Finding the best combination of drugs for each patient takes time. Levodopa (L-dopa, l-3, 4-dihydroxyphenylalanine), the metabolic precursor of dopamine, is the single most effective agent for treating Parkinson’s disease. Levodopa is largely inert; its therapeutic and adverse effects result from the decarboxylation of levodopa to dopamine. Furthermore, a new area being explored in the treatment of Parkinson’s disease is gene therapy. Both non-disease and disease-modifying transgenes are being researched.
""Cell and Gene Therapy in Parkinson’s Disease- Pipeline Insight, 2025"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Cell and Gene Therapy in Parkinson’s Disease pipeline landscape is provided which includes the disease overview and Cell and Gene Therapy in Parkinson’s Disease treatment guidelines. The assessment part of the report embraces, in depth Cell and Gene Therapy in Parkinson’s Disease commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Cell and Gene Therapy in Parkinson’s Disease collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Cell and Gene Therapy in Parkinson’s Disease R&D. The therapies under development are focused on novel approaches to treat/improve Cell and Gene Therapy in Parkinson’s Disease.
This segment of the Cell and Gene Therapy in Parkinson’s Disease report encloses its detailed analysis of various drugs in different stages of clinical development, including Phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Cell and Gene Therapy in Parkinson’s Disease Emerging Drugs
- AB-1005 : Asklepios BioPharmaceutical
- HB-adMSCs: Hope Biosciences
- ANPD 001: Aspen Neuroscience
- BRT-DA01: BlueRock Therapeutics
Further product details are provided in the report……..
Cell and Gene Therapy in Parkinson’s Disease: Therapeutic Assessment
This segment of the report provides insights about the different Cell and Gene Therapy in Parkinson’s Disease drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Cell and Gene Therapy in Parkinson’s Disease
- There are approx. 18+ key companies which are developing the therapies for Cell and Gene Therapy in Parkinson’s Disease. The companies which have their Cell and Gene Therapy in Parkinson’s Disease drug candidates in the most advanced stage, i.e. Phase II include, Asklepios BioPharmaceutical and Hope Biosciences.
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Intravenous
- Subcutaneous
- Parenteral
- Topical
- Molecule Type
- Recombinant fusion proteins
- Small molecule
- Monoclonal antibody
- Peptide
- Polymer
- Gene therapy
- Product Type
Cell and Gene Therapy in Parkinson’s Disease: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Cell and Gene Therapy in Parkinson’s Disease therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Cell and Gene Therapy in Parkinson’s Disease drugs.
Cell and Gene Therapy in Parkinson’s Disease Report Insights
- Cell and Gene Therapy in Parkinson’s Disease Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Cell and Gene Therapy in Parkinson’s Disease drugs?
- How many Cell and Gene Therapy in Parkinson’s Disease drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Cell and Gene Therapy in Parkinson’s Disease?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Cell and Gene Therapy in Parkinson’s Disease therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Cell and Gene Therapy in Parkinson’s Disease and their status?
- What are the key designations that have been granted to the emerging drugs?
- Sumitomo Dainippon Pharma
- BlueRock Therapeutics
- Aspen Neuroscience
- Prevail Therapeutics
- S.Biomedics
- MeiraGTx
- Asklepios BioPharmaceutical
- Hope Biosciences
- CT1 DAP001/DSP 1083
- BRT-DA01
- ANPD 001
- LY3884961
- A9-DPC
- NLX P101
- AB-1005
- HB-adMSCs
Table of Contents
80 Pages
- Introduction
- Executive Summary
- Cell and Gene Therapy in Parkinson’s Disease: Overview
- Introduction
- Causes
- Pathophysiology
- Signs and Symptoms
- Diagnosis
- Treatment
- Pipeline Therapeutics
- Comparative Analysis
- Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
- Cell and Gene Therapy in Parkinson’s Disease– DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- Comparative Analysis
- Drug name: Company name
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Comparative Analysis
- AB-1005 : Asklepios BioPharmaceutical
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- Comparative Analysis
- BRT-DA01: BlueRock Therapeutics
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- Comparative Analysis
- Drug name: Company name
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Inactive Products
- Comparative Analysis
- Cell and Gene Therapy in Parkinson’s Disease Key Companies
- Cell and Gene Therapy in Parkinson’s Disease Key Products
- Cell and Gene Therapy in Parkinson’s Disease- Unmet Needs
- Cell and Gene Therapy in Parkinson’s Disease- Market Drivers and Barriers
- Cell and Gene Therapy in Parkinson’s Disease- Future Perspectives and Conclusion
- Cell and Gene Therapy in Parkinson’s Disease Analyst Views
- Cell and Gene Therapy in Parkinson’s Disease Key Companies
- Appendix
- *The Table of Contents is not exhaustive; will be provided in the final report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
